Elizabeth A. Barrett - 18 Jun 2026 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Reporting relationship: Director
Issuer ticker: ALLO
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 16:26:45 UTC
Prior SEC filing: 19 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/Earl Douglas, Attorney-in-Fact

Key filing fact

Elizabeth A. Barrett filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 23 Jun 2026.

Key facts

This page summarizes Elizabeth A. Barrett's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2026, 16:26.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001764157 Primary reporting owner

Barrett Elizabeth A.

Relationship: Director
Address: 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Signature: /s/Earl Douglas, Attorney-in-Fact
Signature date: 23 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALLO transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +95,400
Change %
Price: $0.000000^*
Shares after: 95,400
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 95,400
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.